JUST OUT📢 @US_FDA 🇺🇸APPROVES fam-trastuzumab deruxtecan-nxki🧪for locally advanced or metastatic #HER2 ➕Gastric or gastroesophageal #Cancer w/prior trastuzumab‼️#GI21

✅OS 12.5 Vs 8.4 mo (iri/pacli)
✅ORR 40.5% Vs 11.3%
✅Median PFS 5.6 Vs 3.5 mo

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC)

163 trials:
-Females comprised 25% authorship (11% had 0 women)
-Female 1st author: 21%, Senior author: 11%
-For publications with IF>20, 13% female first, 0% senior

#GI21

Today the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

#HER2

#GI21 @ASCO #PosterSession
#PARADIGM study of #mFOLFOX6 plus #panitumumab or #bevacizumab as #firstline treatment in patients with #RAS (KRAS/NRAS) wild-type #MetastaticColorectalCancer.

@ASCO_pubs @adbeggs @OncoUgi @nicole_anand @VJHemOnc @VJOncology @SweetNurseOnco